BIOLOGICAL-ACTIVITY OF DIFFERENT CALCITONINS IN MEN

被引:7
作者
GENNARI, C [1 ]
GONNELLI, S [1 ]
AGNUSDEI, D [1 ]
CIVITELLI, R [1 ]
机构
[1] JEWISH HOSP ST LOUIS, DIV ENDOCRINOL & BONE METAB, ST LOUIS, MO 63110 USA
关键词
calcitonin; cAMP; osteoporisis;
D O I
10.1016/0531-5565(90)90071-9
中图分类号
R592 [老年病学]; C [社会科学总论];
学科分类号
03 ; 0303 ; 100203 ;
摘要
Calcitonin has been isolated and its structure defined from several species, including man. Synthetic preparations of several calcitonins are available for clinical use. Of these, porcine (pCT), human (hCT), and salmon (sCT) have been synthetized according to their natural sequences, while eel calcitonin (cCT) is available as amino-suberic acid derivative (ASU-eCT). The different molecular configuration results in different biological potency and tolerability. Currently, the potency of calcitonin in man is evaluated by its capacity of lowering serum calcium and stimulating cAMP plasma levels after acute infusion. In normal subjects, cAMP stimulation seems to be a more sensitive test, since plasma calcium in normal subjects is poorly affected by an acute treatment with calcitonin. On the other hand, the side effects are usually assessed by clinical observation, on the basis of duration and intensity of the symptoms. Our experience, emerging from several studies devoted to comparing the biological activity and tolerability of different calcitonin preparations in humans, indicates that the hypocalcemic effect and the increase of plasma cAMP are produced by all peptides, according to the potency ordersCT > hCT > ASU-eCT. For all peptides, the most constant side effects is flushing, and the frequency order of side effects is hCT > sCT = ASU-eCT. © 1990.
引用
收藏
页码:339 / 347
页数:9
相关论文
共 30 条
[1]  
AZRIA M, 1986, CURRENT CLIN PRAC 42, P104
[2]  
BANGHAM DR, 1983, LANCET, V1, P926
[3]   EFFECTS OF PARATHYROID-HORMONE AND CALCITONIN ON PLASMA AND NEPHROGENOUS CYCLIC ADENOSINE-3',5'-MONOPHOSPHATE IN NORMAL SUBJECTS AND IN PATHOLOGICAL CONDITIONS [J].
CANIGGIA, A ;
GENNARI, C ;
LORE, F ;
NUTI, R ;
GALLI, M .
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 1980, 10 (02) :99-105
[4]  
CANIGGIA A, 1985, INT C SERIES, V663, P167
[5]   THE EFFECT OF HUMAN CALCITONIN ON THE CYTOPLASMIC SPREADING OF RAT OSTEOCLASTS [J].
CHAMBERS, TJ ;
CHAMBERS, JC ;
SYMONDS, J ;
DARBY, JA .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1986, 63 (05) :1080-1085
[6]   THE SENSITIVITY OF ISOLATED OSTEOCLASTS TO MORPHOLOGICAL TRANSFORMATION BY CALCITONIN [J].
CHAMBERS, TJ ;
MOORE, A .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1983, 57 (04) :819-824
[7]  
CHAMBERS TJ, 1988, TRIANGLE, V27, P53
[8]  
CHIERICHETTI SM, 1984, OSTEOPOROSIS SOCIAL, P249
[9]   EVIDENCE FOR CALCITONIN - A NEW HORMONE FROM PARATHYROID THAT LOWERS BLOOD CALCIUM [J].
COPP, DH ;
DAVIDSON, AG ;
HENZE, KG ;
CHENEY, BA ;
CAMERON, EC .
ENDOCRINOLOGY, 1962, 70 (05) :638-+
[10]  
DOEPFNER WEH, 1983, TRIANGLE, V22, P57